Background Despite the important role of amyloid-beta protein (Aβ) in initiation and progression Alzheimer’s Disease (AD), precise mechanism by which Aβ disrupts neuronal activity (NA) structure during disease development, whether this is an appropriate therapeutic target still controversial. Recently, we introduced several novel NA metrics (Kazemeifar, PLoS One 2017; Haddad, ISMRM 2019) based ...
